<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751175</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2012-002518-38</org_study_id>
    <nct_id>NCT04751175</nct_id>
  </id_info>
  <brief_title>Management of Pain in Lumbar Arthrodesis</brief_title>
  <acronym>KETASONA</acronym>
  <official_title>Ketamine and Dexametasone in the Management of Pain in Lumbar Arthrodesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KETAMINE AND DEXAMETASONE IN THE MANAGEMENT OF PAIN IN LUMBAR ARTHRODESISPhase IV prospective&#xD;
      randomized controlled single-center clinical trial to determine the effect of intravenous&#xD;
      ketamine and dexamethasone administration perioperatively in patients undergoing lumbar&#xD;
      arthrodesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The need to carry out this study is to evaluate the analgesic effects after the&#xD;
      administration of ketamine and dexamethasone intravenously perioperatively in patients&#xD;
      undergoing lumbar arthrodesis and, likewise, study the incidence of pain and protocolize&#xD;
      perioperative analgesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center, controlled, prospective and randomized clinical trial, phase IV, to determine the effect of perioperative intravenous administration of ketamine and dexamethasone in patients undergoing lumbar arthrodesis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>To preserve the masking of the study, the randomization system has been carried out by the pharmacy service personnel using the EPIDAT 4.0 program and only the personnel responsible for the pharmacy will know the randomization tables and codes. The main investigator will have the emergency codes in case of need by contacting the pharmacy service</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Morphic Chloride (PCA) to treat pain during the post-operative period. Consumption of morphics will be evaluated</measure>
    <time_frame>4 hours post operative</time_frame>
    <description>Consumption of morphics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting (PONV).</measure>
    <time_frame>4 hours post operative</time_frame>
    <description>Incidence of postoperative nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficay of study treatment regarding pain at 3 postoperative months</measure>
    <time_frame>3 months</time_frame>
    <description>Pain at 3 postoperative months assessed by EVA scale pain. This is a visual analogue scale regarding pain.It consists of a 10-centimeter horizontal line, at the ends of which are the extreme expressions of a symptom. In the left is the absence or less intensity and in the right the greater intensity. The patient is asked to mark on the line the point that indicates the intensity and measure it with a millimeter ruler. The intensity is expressed in centimeters or millimeters. The evaluation will be: 1.Mild pain if the patient scores pain less than 3. 2.Moderate pain if the evaluation is between 4 and 7. 3.Severe pain if the evaluation is equal to or greater than 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse side effects:Hallucinations / Delirium.Sedation. Diplopia, Hyperglycemia Respiratory depression (Sat &lt;90%)</measure>
    <time_frame>4 hours post operative</time_frame>
    <description>Rate of patients that presented adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ketamina bolus plus Dexamethasone bolus plus infusion ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine bolus plus ketamine infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexametasone arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline bolus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization</description>
    <arm_group_label>Ketamina bolus plus Dexamethasone bolus plus infusion ketamine</arm_group_label>
    <arm_group_label>Ketamine bolus plus ketamine infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.&#xD;
Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration</description>
    <arm_group_label>Dexametasone arm</arm_group_label>
    <arm_group_label>Ketamina bolus plus Dexamethasone bolus plus infusion ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>placebo</description>
    <arm_group_label>Dexametasone arm</arm_group_label>
    <arm_group_label>Ketamine bolus plus ketamine infusion</arm_group_label>
    <arm_group_label>Saline bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  ASA I-III.&#xD;
&#xD;
          -  Lumbar arthrodesis.&#xD;
&#xD;
          -  Patients who have signed the preoperative informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable coronary heart disease&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  History of allergy to ketamine, dexamethasone, or morphic chloride&#xD;
&#xD;
          -  Dementia or inability to understand IC and study&#xD;
&#xD;
          -  Pluricomplicated diabetes mellitus difficult to control&#xD;
&#xD;
          -  Patients who have taken an experimental drug 30 days before the start of the study or&#xD;
             who are included in any type of study of an experimental drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emili Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Dr Josep Trueta and Hospital Santa Caterina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Martinez, Sc</last_name>
    <phone>972940200</phone>
    <phone_ext>2343</phone_ext>
    <email>cmartinez@idibgi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emili Leon, MD</last_name>
    <phone>972940200</phone>
    <email>emili_leon@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Martinez, MSc</last_name>
      <phone>972940200</phone>
      <phone_ext>2343</phone_ext>
      <email>cmartinez@idibgi.org</email>
    </contact>
    <investigator>
      <last_name>Emili Leon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Bellod, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noelia Rios, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</investigator_affiliation>
    <investigator_full_name>Dr Emili Leon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

